Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.

Graham DJ, Williams JR, Hsueh YH, Calia K, Levenson M, Pinheiro SP, Macurdy TE, Shih D, Worrall C, Kelman JA.

Mov Disord. 2013 Apr;28(4):490-7. doi: 10.1002/mds.25351. Epub 2013 Feb 26.

PMID:
23443994
2.

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.

PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE.

Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Erratum in: Lancet. 2014 Sep 27;384(9949):1186.

PMID:
24928805
3.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.

Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060. Erratum in: Ann Neurol. 2010 Sep;68(3):412-3.

PMID:
20582993
4.
5.

Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.

Pahwa R.

J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):4-10. Review.

PMID:
17948613
6.

Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

Stowe R, Ives N, Clarke CE, Deane K; van Hilten, Wheatley K, Gray R, Handley K, Furmston A.

Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166. doi: 10.1002/14651858.CD007166.pub2. Review.

PMID:
20614454
7.

Pooled analysis of phase III with entacapone in Parkinson's disease.

Kuoppamäki M, Vahteristo M, Ellmén J, Kieburtz K.

Acta Neurol Scand. 2014 Oct;130(4):239-47. doi: 10.1111/ane.12278. Epub 2014 Sep 3.

PMID:
25186800
9.
10.

Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .

Jog M, Panisset M, Suchowersky O, Réhel B, Schecter R.

Curr Med Res Opin. 2008 Nov;24(11):3207-15. doi: 10.1185/03007990802430518 . Epub 2008 Oct 14.

PMID:
18922214
11.

Treatment of advanced Parkinson's disease in the United States: a cost-utility model.

Groenendaal H, Tarrants ML, Armand C.

Clin Drug Investig. 2010;30(11):789-98. doi: 10.2165/11538520-000000000-00000.

PMID:
20818839
13.

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.

Kuoppamäki M, Leinonen M, Poewe W.

J Neural Transm (Vienna). 2015 Dec;122(12):1709-14. doi: 10.1007/s00702-015-1449-6. Epub 2015 Sep 7.

14.

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J; US01 Study Team.

Arch Neurol. 2004 Oct;61(10):1563-8.

PMID:
15477510
15.

Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.

Fénelon G, Giménez-Roldán S, Montastruc JL, Bermejo F, Durif F, Bourdeix I, Péré JJ, Galiano L, Schadrack J.

J Neural Transm (Vienna). 2003 Mar;110(3):239-51.

PMID:
12658373
16.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
17.

Entacapone. A review of its use in Parkinson's disease.

Holm KJ, Spencer CM.

Drugs. 1999 Jul;58(1):159-77. Review.

PMID:
10439935
18.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Najib J.

Clin Ther. 2001 Jun;23(6):802-32; discussion 771. Review.

PMID:
11440283
19.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
20.

Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.

Jenner P.

Neurology. 2004 Jan 13;62(1 Suppl 1):S47-55. Review.

PMID:
14718680

Supplemental Content

Support Center